Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches.
adherence
latent tuberculosis infection
nurse case manager
telemonitoring
treatment
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
07
2023
accepted:
17
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Contact tracing and treatment of latent tuberculosis infection (LTBI) is a key element of tuberculosis (TB) control in low TB incidence countries. A TB control and prevention program has been active in the Basque Country since 2003, including the development of the nurse case manager role and a unified electronic record. Three World Health Organization-approved LTBI regimens have been used: isoniazid for 6 months (6H), rifampicin for 4 months (4R), and isoniazid and rifampicin for 3 months (3HR). Centralized follow-up by a TB nurse case manager started in January 2016, with regular telephone follow-up, telemonitoring of blood test results, and monitoring of adherence by electronic review of drugs dispensed in pharmacies. To estimate LTBI treatment completion and toxicity of different preventive treatment regimens in a real-world setting. Secondary objective: to investigate the adherence to different approaches to preventive treatment monitoring. A multicentre retrospective cohort study was conducted using data collected prospectively on contacts of patients with TB in five hospitals in Biscay from 2003 to 2022. A total of 3,066 contacts with LTBI were included. The overall completion rate was 66.8%; 86.5% of patients on 3HR ( 3HR was well tolerated and associated with a higher rate of treatment completion. Patients with nurse telemonitoring follow-up had better completion rates.
Identifiants
pubmed: 38020141
doi: 10.3389/fmed.2023.1265057
pmc: PMC10651218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1265057Informations de copyright
Copyright © 2023 Ortiz Laza, Lopez Aranaga, Toral Andres, Toja Uriarte, Santos Zorrozua, Altube Urrengoechea, Garros Garay and Tabernero Huguet.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Tuberc Lung Dis. 2015 Jan;19(1):31-8
pubmed: 25519787
Int J Tuberc Lung Dis. 2015 Jul;19(7):799-804
pubmed: 26056104
J Public Health Manag Pract. 2021 Jul-Aug 01;27(4):E151-E161
pubmed: 31688742
Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296
pubmed: 28087928
Int J Tuberc Lung Dis. 2013 Mar;17(3):326-32
pubmed: 23407221
Int J Tuberc Lung Dis. 2010 Jun;14(6):701-7
pubmed: 20487607
Expert Rev Respir Med. 2020 Feb;14(2):195-208
pubmed: 31760848
Eur Respir J. 2019 Jan 17;53(1):
pubmed: 30655449
Int J Tuberc Lung Dis. 2014 Apr;18(4):421-7
pubmed: 24670696
N Engl J Med. 2011 Dec 8;365(23):2155-66
pubmed: 22150035
J Clin Med. 2019 Dec 31;9(1):
pubmed: 31906078
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
Int J Tuberc Lung Dis. 2013 Sep;17(9):1178-85
pubmed: 23928167
Clin Infect Dis. 2018 Jan 18;66(3):396-403
pubmed: 29020191
BMC Infect Dis. 2016 May 17;16:204
pubmed: 27184748
Infect Dis (Lond). 2018 Sep;50(9):678-686
pubmed: 29620426
BMC Public Health. 2021 May 21;21(1):964
pubmed: 34020616
Eur J Public Health. 2022 Aug 1;32(4):643-647
pubmed: 35325093
Int J Med Inform. 2022 Mar;159:104687
pubmed: 35007924
Arch Bronconeumol (Engl Ed). 2020 Dec 31;:
pubmed: 33526297
Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1344-1349
pubmed: 30355415
Int J Tuberc Lung Dis. 2016 Aug;20(8):1065-71
pubmed: 27393541
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11
pubmed: 32053584
Ann Intern Med. 2017 Aug 15;167(4):248-255
pubmed: 28761946